The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

DNAI1  -  dynein, axonemal, intermediate chain 1

Homo sapiens

Synonyms: Axonemal dynein intermediate chain 1, CILD1, DIC1, Dynein intermediate chain 1, axonemal, ICS1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of DNAI1


Psychiatry related information on DNAI1

  • Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men [5].
  • 2. This study investigated the effects of ICS 205-930 on gastric emptying of an isotopically labelled semisolid 1168 kJ meal and on antral contractility in patients with primary anorexia nervosa, a condition frequently associated with impaired gastric motor function [6].
  • Wheel running is known to show estrous-related changes while reports upon intracranial reinforcement (self-stimulation, ICS) have been equivocal [7].
  • METHOD: Integrated Case Studies and Medical Decision Making (ICS) is the final course of the second year at the University of Pittsburgh School of Medicine. In ICS, 16 groups of nine students work in a PBL format over seven weeks [8].

High impact information on DNAI1

  • The presence of circulating immune complexes (ICS) in freshly drawn sera of 67 children with neuroblastoma was studied by the Raji cell radioimmunoassay of Theofilopoulos et al [2].
  • DNAI1 is highly expressed in trachea and testis and is composed of 20 exons located at 9p13-p21 [9].
  • PATIENTS AND METHODS: We applied a novel statistical approach to investigate whether the efficacy of the 5HT3 receptor antagonist ICS 205-930 (tropisetron) is maintained over repeated cycles of weekly high-dose cisplatin [10].
  • Both the behavioral and electrophysiological effects were blocked not only by the 5-HT3 antagonists zacopride and ICS 205-930, but also by antagonists to the inhibitory amino acid GABA [11].
  • Here, we investigated flagellum behaviour in normal and mutant trypanosome cell lines where expression of genes encoding various axoneme proteins (PF16, PF20, DNAI1, LC2) had been silenced by RNAi [12].

Chemical compound and disease context of DNAI1


Biological context of DNAI1


Anatomical context of DNAI1


Associations of DNAI1 with chemical compounds

  • Infusion of 5-HT caused significant net secretion of water after placebo (2.05 (0.58) ml/cm x h; p < 0.02) as well as ICS 205-930 (2.60 (0.89) ml/cm x h; p < 0.05) [23].
  • The current induced by the 2,3,5-trichloro-PBG derivative was inhibited by the specific 5-HT3 receptor antagonist ICS 205-930 but was unaffected by the 5-HT2 receptor antagonist ketanserin [27].
  • It is synthesized from chorismate in a reaction catalyzed by the enzyme isochorismate synthase (ICS; EC [28].
  • RESULTS: By using capsaicin cough sensitivity as the basis for grouping the study subjects, we divided the patients into 2 groups: an increased cough sensitivity group (ICS, C5 <32 mumol/L) and a normal cough sensitivity (NCS) group [29].
  • OBJECTIVE: Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 microg/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients) [30].

Other interactions of DNAI1

  • To date, autosomal recessive mutations have only been identified in a small number of patients involving DNAI1 and DNAH5, which encode outer dynein arm components [31].

Analytical, diagnostic and therapeutic context of DNAI1

  • When patients with stage IV disease were subdivided into "before," "during," and "after" treatment groups, there was a significant decrease in ICS levels as treatment progressed [2].
  • Gel filtration of the affinity purified material yielded a single peak labeled by [3H]Q ICS 205-930 with an apparent molecular size of 250,000, which was also composed of two bands of 54,000 and 38,000, consistent with these being the constituents of the 5-HT3 receptor [32].
  • The effects of the 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930 (tropisetron), on basal and 5-HT induced jejunal secretion of water and electrolytes were examined using a double blind, randomised crossover design [23].
  • We have purified ICS to homogeneity from elicited Catharanthus roseus cell cultures [28].
  • Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices [33].


  1. Axonemal dynein intermediate-chain gene (DNAI1) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome). Guichard, C., Harricane, M.C., Lafitte, J.J., Godard, P., Zaegel, M., Tack, V., Lalau, G., Bouvagnet, P. Am. J. Hum. Genet. (2001) [Pubmed]
  2. Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease. Brandeis, W.E., Helson, L., Wang, Y., Good, R.A., Day, N.K. J. Clin. Invest. (1978) [Pubmed]
  3. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Leibundgut, U., Lancranjan, I. Lancet (1987) [Pubmed]
  4. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Scanlon, P.D., Connett, J.E., Wise, R.A., Tashkin, D.P., Madhok, T., Skeans, M., Carpenter, P.C., Bailey, W.C., Buist, A.S., Eichenhorn, M., Kanner, R.E., Weinmann, G. Am. J. Respir. Crit. Care Med. (2004) [Pubmed]
  5. Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men. Stacher, G., Gaupmann, G., Schneider, C., Stacher-Janotta, G., Steiner-Mittelbach, G., Abatzi, T.A., Steinringer, H. British journal of clinical pharmacology. (1989) [Pubmed]
  6. Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa. Stacher, G., Bergmann, H., Granser-Vacariu, G.V., Wiesnagrotzki, S., Wenzelabatzi, T.A., Gaupmann, G., Kugi, A., Steinringer, H., Schneider, C., Höbart, J. British journal of clinical pharmacology. (1991) [Pubmed]
  7. Detailed analysis of estrous-related changes in wheel running and self-stimulation. Steiner, M., Katz, R.J., Carroll, B.J. Physiol. Behav. (1982) [Pubmed]
  8. Interrater concordance for faculty grading of student performances in a problem-based learning course. Schor, N.F., Troen, P., Kanter, S.L., Janosky, J.E. Academic medicine : journal of the Association of American Medical Colleges. (1997) [Pubmed]
  9. Loss-of-function mutations in a human gene related to Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia. Pennarun, G., Escudier, E., Chapelin, C., Bridoux, A.M., Cacheux, V., Roger, G., Clément, A., Goossens, M., Amselem, S., Duriez, B. Am. J. Hum. Genet. (1999) [Pubmed]
  10. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. de Wit, R., Schmitz, P.I., Verweij, J., de Boer-Dennert, M., de Mulder, P.H., Planting, A.S., van der Burg, M.E., Stoter, G. J. Clin. Oncol. (1996) [Pubmed]
  11. Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. Alhaider, A.A., Lei, S.Z., Wilcox, G.L. J. Neurosci. (1991) [Pubmed]
  12. Conserved and specific functions of axoneme components in trypanosome motility. Branche, C., Kohl, L., Toutirais, G., Buisson, J., Cosson, J., Bastin, P. J. Cell. Sci. (2006) [Pubmed]
  13. Hyperalgesia due to nerve damage: role of nerve growth factor. Theodosiou, M., Rush, R.A., Zhou, X.F., Hu, D., Walker, J.S., Tracey, D.J. Pain (1999) [Pubmed]
  14. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Meyer, J.S., Wittliff, J.L. Int. J. Cancer (1991) [Pubmed]
  15. The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome. Coupe, M.O., Anderson, J.V., Morris, J.A., Alstead, E.M., Bloom, S.R., Hodgson, H.J. Aliment. Pharmacol. Ther. (1988) [Pubmed]
  16. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Costall, B., Domeney, A.M., Naylor, R.J., Owera-Atepo, J.B., Rudd, J.A., Tattersall, F.D. Neuropharmacology (1990) [Pubmed]
  17. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Costall, B., Domeney, A.M., Naylor, R.J., Tattersall, F.D. Neuropharmacology (1986) [Pubmed]
  18. Germline mutations in an intermediate chain dynein cause primary ciliary dyskinesia. Zariwala, M., Noone, P.G., Sannuti, A., Minnix, S., Zhou, Z., Leigh, M.W., Hazucha, M., Carson, J.L., Knowles, M.R. Am. J. Respir. Cell Mol. Biol. (2001) [Pubmed]
  19. Mutations of DNAI1 in Primary Ciliary Dyskinesia: Evidence of Founder Effect in a Common Mutation. Zariwala, M.A., Leigh, M.W., Ceppa, F., Kennedy, M.P., Noone, P.G., Carson, J.L., Hazucha, M.J., Lori, A., Horvath, J., Olbrich, H., Loges, N.T., Bridoux, A.M., Pennarun, G., Duriez, B., Escudier, E., Mitchison, H.M., Chodhari, R., Chung, E.M., Morgan, L.C., de Iongh, R.U., Rutland, J., Pradal, U., Omran, H., Amselem, S., Knowles, M.R. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  20. Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Akkermans, L.M., Vos, A., Hoekstra, A., Roelofs, J.M., Horowitz, M. Gut (1988) [Pubmed]
  21. DNA-protein interactions at the interferon-responsive promoter: evidences for an involvement of phosphorylation. Roy, C., Lebleu, B. Nucleic Acids Res. (1990) [Pubmed]
  22. 5-Hydroxytryptamine facilitates cholinergic bronchoconstriction in human and guinea pig airways. Takahashi, T., Ward, J.K., Tadjkarimi, S., Yacoub, M.H., Barnes, P.J., Belvisi, M.G. Am. J. Respir. Crit. Care Med. (1995) [Pubmed]
  23. Failure of tropisetron to inhibit jejunal water and electrolyte secretion induced by 5-hydroxytryptamine in healthy volunteers. Munck, L.K., Eskerod, O., Hansen, M.B., Bukhave, K., Rask-Madsen, J. Gut (1994) [Pubmed]
  24. The psychopharmacology of 5-HT3 receptors. Costall, B., Naylor, R.J., Tyers, M.B. Pharmacol. Ther. (1990) [Pubmed]
  25. Subdivisions of the inferior colliculus in the barn owl (Tyto alba). Knudsen, E.I. J. Comp. Neurol. (1983) [Pubmed]
  26. Storage of human platelet concentrates in an artificial medium without dextrose. Adams, G.A., Rock, G. Transfusion (1988) [Pubmed]
  27. Biguanide derivatives: agonist pharmacology at 5-hydroxytryptamine type 3 receptors in vitro. Morain, P., Abraham, C., Portevin, B., De Nanteuil, G. Mol. Pharmacol. (1994) [Pubmed]
  28. Purification and cDNA cloning of isochorismate synthase from elicited cell cultures of Catharanthus roseus. van Tegelen, L.J., Moreno, P.R., Croes, A.F., Verpoorte, R., Wullems, G.J. Plant Physiol. (1999) [Pubmed]
  29. Elevated substance P levels in nasal lavage fluids from patients with chronic nonproductive cough and increased cough sensitivity to inhaled capsaicin. Cho, Y.S., Park, S.Y., Lee, C.K., Yoo, B., Moon, H.B. J. Allergy Clin. Immunol. (2003) [Pubmed]
  30. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. Wolfe, J., Rooklin, A., Grady, J., Munk, Z.M., Stevens, A., Prillaman, B., Duke, S., Harding, S. J. Allergy Clin. Immunol. (2000) [Pubmed]
  31. DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. Hornef, N., Olbrich, H., Horvath, J., Zariwala, M.A., Fliegauf, M., Loges, N.T., Wildhaber, J., Noone, P.G., Kennedy, M., Antonarakis, S.E., Blouin, J.L., Bartoloni, L., Nüsslein, T., Ahrens, P., Griese, M., Kuhl, H., Sudbrak, R., Knowles, M.R., Reinhardt, R., Omran, H. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  32. Purification of the 5-hydroxytryptamine 5-HT3 receptor from NCB20 cells. McKernan, R.M., Gillard, N.P., Quirk, K., Kneen, C.O., Stevenson, G.I., Swain, C.J., Ragan, C.I. J. Biol. Chem. (1990) [Pubmed]
  33. Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices. Metcalfe, S., Moodie, P. J. Allergy Clin. Immunol. (2004) [Pubmed]
WikiGenes - Universities